Yarrow Bioscience (YARW) Assets (2016 - 2026)
Yarrow Bioscience's (YARW) quarterly Assets came in at $25.9 million in Q1 2026, down 54.14% YoY from $56.4 million in Q1 2025, and down 14.21% on a QoQ basis from $30.2 million in Q4 2025.
Yarrow Bioscience (YARW) Assets (2016 - 2026) Analysis & Trends
Yarrow Bioscience (YARW) has 11 years of Assets data on file, last reported at $25.9 million in Q1 2026.
- Quarterly Assets fell 54.14% year-over-year to $25.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.9 million (down 54.14% YoY) and the FY2025 annual result came in at $30.2 million, down 54.92% from the prior year.
- Assets fell to $25.9 million in Q1 2026, from $30.2 million in the prior quarter.
- In the past five years, Assets ranged from a high of $97.7 million in Q4 2023 to a low of $19.3 million in Q3 2023.
- A 5-year average of $53.9 million and a median of $51.0 million in 2022 frame the typical range for Assets.
- Annual changes were most pronounced in 2023 — Assets sank 58.93% — and 2024, when it surged 295.48%.
- Tracing YARW's Assets over 5 years: stood at $40.8 million in 2022, then surged by 139.67% to $97.7 million in 2023, then sank by 31.51% to $66.9 million in 2024, then slumped by 54.92% to $30.2 million in 2025, then retreated by 14.21% to $25.9 million in 2026.
- The last three Assets figures came in at $25.9 million (Q1 2026), $30.2 million (Q4 2025), and $44.7 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.56 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.10 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.60 Bn |
| 10 | Yarrow Bioscience | 32.54 Mn | 9.62 Mn | - | 23.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 23.60 Mn |
| Mar 31, 2026 | 25.87 Mn |
| Dec 31, 2025 | 30.16 Mn |
| Jun 30, 2025 | 44.72 Mn |
| Mar 31, 2025 | 56.42 Mn |
| Dec 31, 2024 | 66.91 Mn |
| Sep 30, 2024 | 76.20 Mn |
| Jun 30, 2024 | 86.65 Mn |
| Mar 31, 2024 | 91.68 Mn |
| Dec 31, 2023 | 97.69 Mn |
| Sep 30, 2023 | 19.27 Mn |
| Jun 30, 2023 | 24.96 Mn |
| Mar 31, 2023 | 35.26 Mn |
| Dec 31, 2022 | 40.76 Mn |
| Sep 30, 2022 | 46.91 Mn |
| Jun 30, 2022 | 55.19 Mn |
| Mar 31, 2022 | 64.32 Mn |
| Dec 31, 2021 | 67.05 Mn |
| Sep 30, 2021 | 81.32 Mn |
| Jun 30, 2021 | 133.98 Mn |